

DAFTAR PUSTAKA

1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 Infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* 2020 Jul 1;24:91–8.
2. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Napoli R Di. Features, evaluation, and treatment of coronavirus (COVID-19) [Internet]. StatPearls Publishing; 2022 [diakses pada 2022 Dec 29]. [https://pubmed.ncbi.nlm.nih.gov/32150360/#:~:text=Coronavirus%20disease%202019%20\(COVID%2D19,global%20health%20crisis%20since%20the](https://pubmed.ncbi.nlm.nih.gov/32150360/#:~:text=Coronavirus%20disease%202019%20(COVID%2D19,global%20health%20crisis%20since%20the)
3. Acosta RAH, Garrigos ZE, Marcelin JR, Vijayvargiya P. COVID-19 pathogenesis and clinical manifestations. *Infect Dis Clin North Am.* 2022 Jun 1;36(2):231–49.
4. Burhan E, Susanto AD, Isbaniah F, Nasution SA, Ginanjar E, Pitoyo CW, et al. Pedoman tatalaksana COVID-19 edisi 4. 2022.
5. Costa L, Martins J, Costa M, Oliveira AI, Leal D, Lencastre L. Clinical characteristics and mortality-associated factors in COVID-19 critical patients in a Portuguese ICU. *Cureus.* 2022 Sep 26.
6. Abdi S, Nemati S, Darbaghshahi NN, Mohammadi M, Saeedi E, Najji P, et al. Trends of in hospital and ICU mortality in COVID-19 patients over the fourth and fifth COVID-19 surges in Iran: A Retrospective cohort study from Iran. *International Journal for Quality in Health Care.* 2022 Jul 1;34(3).
7. Ariani P. Hubungan kadar c-reactive protein, kadar feritin, dengan luaran pada pasien coronavirus disease 2019 di intensive care unit COVID RSUP. DR. M. DJAMIL Padang periode Juli - Desember 2021 [Internet]. [Padang]: Universitas Andalas; 2023 [diakses pada 2023 Apr 11]. <http://scholar.unand.ac.id/id/eprint/123264>
8. Lubis B, Fatoni AZ, Fadhlurrahman AF, Siswagama TA, Vitraludyono R, Lestari MI, et al. Mortality rate of COVID-19 patients in intensive care unit: A Multicentre retrospective observational study. *Journal of Medicinal and Chemical Sciences.* 2023 Apr 1;6(4):764–70.
9. Rahmat AS, Sari FJ. Komorbid pada kasus kematian pasien COVID-19. Bekasi; 2022.
10. Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT, et al. ICU and ventilator mortality among critically ill adults with COVID-19 [Internet]. medRxiv : the preprint server for health sciences. 2020 Apr. <http://www.ncbi.nlm.nih.gov/pubmed/32511599>
11. Loomba RS, Villarreal EG, Farias JS, Aggarwal G, Aggarwal S, Flores S. Serum biomarkers for prediction of mortality in patients with COVID-19. *Ann Clin Biochem.* 2022 Jan 1;59(1):15–22.
12. Khatib MY, Ananthegowda DC, Elshafei MS, El-Zeer H, Abdaljawad WI, Shaheen MA, et al. Predictors of mortality and morbidity in critically ill COVID-19 patients: An experience from a low mortality country. *Health Sci Rep.* 2022 May 1;5(3).

13. Lee M, Lim JS, Kim CH, Lee SH, Kim Y, Hun Lee J, et al. High neutrophil-lymphocyte ratio predicts post-stroke cognitive impairment in acute ischemic stroke patients. *Front Neurol*. 2021 Jul 1;12.
14. Bedel C, Korkut M. Evaluation of the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte lymphocyte ratio for diagnosis of testicular torsion. *Journal of Acute Disease*. 2020;9(5):213.
15. Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. *Ann Hepatol*. 2021 May 1;22.
16. Alagbe A, Pedroso G, Oliveira B, Maia A, Costa E, Albuquerque D, et al. Association of lymphocyte counts, NLR, and PLR with mortality in COVID-19 patients. *Hematol Transfus Cell Ther*. 2021 Oct;43:S508–9.
17. Sarkar S, Kannan S, Khanna P, Singh AK. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. *J Med Virol*. 2022 Jan 1;94(1):211–21.
18. Erdogan A, Can FE, Gönüllü H. Evaluation of the prognostic role of NLR, LMR, PLR, and LCR ratio in COVID-19 patients. *J Med Virol*. 2021 Sep 1;93(9):5555–9.
19. Simon P, Le Borgne P, Lefevbre F, Cipolat L, Remillon A, Dib C, et al. Platelet-to-lymphocyte ratio (PLR) is not a predicting marker of severity but of mortality in COVID-19 patients admitted to the emergency department: A retrospective multicenter study. *J Clin Med*. 2022 Aug 1;11(16).
20. Sunil R, Ramesh PC, Nagaraj AH, Kadarappa K. Utility of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) as a predictor of mortality in COVID-19. *Medical Laboratory Technology Journal*. 2022 Apr 17.
21. Nasrani L. Hubungan neutrophil-lymphocyte ratio, absolute lymphocyte count, dan platelet lymphocyte ratio terhadap derajat keparahan COVID-19. *Intisari Sains Medis [Internet]*. 2022 Feb 28;13(1):127–30. <https://isainsmedis.id/index.php/ism/article/view/1241>
22. Gao YD, Ding M, Dong X, Zhang JJ, Azkur AK, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy: European Journal of Allergy and Clinical Immunology*. 2021 Feb 1;76(2):428–55.
23. Usman E, Katar Y. Association of blood type and mortality of covid-19: a hospital-based study in national referral hospital, Indonesia. *J Infect Dis*. 2023;17(2):23–7.
24. Masrul M, Usman E, Febri DS. Obesity and outcome among patients hospitalized SARS-Cov-2: a hospital-based study in Indonesia. *J Infect Dis*. 2023;17(2):28–33.
25. Nindrea RD, Lailani M, Masrul, Usman E, Katar Y, Hendriyani H, et al. Obesity and mortality of hospitalized COVID-19 patients in Asian and Western countries: A systematic review and meta-analysis. *Int J Prev Med*. 2023.
26. World Health Organization. Report of the WHO-China joint mission on Coronavirus Disease 2019 (COVID-19). *Mission China Joint*. 2019. 16–24 p.

27. Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. *Rev Med Virol*. 2020 Sep 1;30(5).
28. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: The role of androgens in disease severity and progression. *Endocrine*. 2021 Jan 1;71(1):3–8.
29. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med*. 2020 Apr 1;8(4):e20.
30. Oguz H, Okan YB. Endocrine disorders and COVID-19. *Annu Rev Med* 2023 [Internet]. 2023;74:75–88.
31. Yuniarti T, Maesaroh S, Dewi LA, Tri Atmojo J, Widiyanto A. Risiko keparahan pada pasien COVID-19 dengan komorbiditas penyakit ginjal : Meta-analisis. *Jurnal Ilmiah STIKES Kendal* [Internet]. 2023; <http://journal.stikeskendal.ac.id/index.php/PSKM>
32. Somalinggi EENA, Wantania FEN, Waleleng BJ. Komorbid kardiovaskular dan gastrointestinal pada coronavirus disease 2019 (COVID-19). *Medical Scope Journal*. 2023 Mar 23;4(2):186–92.
33. Godani M, Beronio A, Lanza G. Post COVID-19 myoclonus–ataxia syndrome responsive to intravenous immunoglobulins. *Mov Disord Clin Pract* [Internet]. 2022 Sep 11;9(S2).
34. Georgakopoulou VE, Lembessis P, Skarlis C, Gkoufa A, Sipsas NV., Mavragani CP. Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes. *Front Med (Lausanne)*. 2022 Mar 17;9.
35. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. *Cancer Discov*. 2020 Jun 1;10(6):783.
36. Лурье ТВ, Федулов АС, Дрик ОН, Санкович ЕВ. Multisistem inflammatory syndrome in adult patients associated with COVID-19 in clinical practice of a neurologist: A case report. *Неврология и нейрохирургия Восточная Европа*. 2022 Nov 2;3(3):336–48.
37. de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. *Diabetol Metab Syndr*. 2020 Aug 31;12(1).
38. Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. *Diabetes Metab*. 2021 Mar 1;47(2).
39. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev*. 2020 Oct 1;36(7).
40. Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: hypothesis or evidence? *J Clin Hypertens (Greenwich)*. 2020 Jul 1;22(7):1120–6.
41. South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) receptor blocker use during the pandemic: The pediatric perspective. *Hypertension*. 2020 Jul 1;76(1):16–22.

42. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020 Jul 1;14(4):303–10.
43. Cetinkaya EA. Coincidence of COVID-19 infection and smell-taste perception disorders. *Journal of Craniofacial Surgery*. 2020 Sep 1;31(6):E625–6.
44. Ko JY, Desisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among U.S. delivery hospitalizations with and without a COVID-19 diagnosis. Oxford University Press for the Infectious Diseases Society of America. 2021.
45. Sultanoglu H, Demir MC, Bogan M. Tren penerimaan unit gawat darurat trauma geriatri selama COVID-19. *Jurnal Keperawatan Trauma* 29(3):p 125-130, 2022.
46. Ding L, Wei J, Wang B. The impact of COVID-19 on the prevalence, mortality, and associated risk factors for mortality in patients with hip fractures: A meta-analysis. *J Am Med Dir Assoc*. 2023 Jun 1;24(6):846–54.
47. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine*. 2020 Feb 20;382(8):727–33.
48. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020 Jul 1;24:91–8.
49. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clinical Immunology*. 2020 Jun 1;215.
50. Bergmann CC, Silverman RH. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. *Cleve Clin J Med*. 2020;87(5):321–7.
51. Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. *Pharmacological Reports*. 2021 Dec 1;73(6):1539–50.
52. Meirelles L. Oral mucosa shows high expression of ACE2 receptor of 2019-nCoV. 2020;
53. Musazadeh V, Karimi A, Bagheri N, Jafarzadeh J, Sanaei S, Vajdi M, et al. The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms. *Biomedicine and Pharmacotherapy*. 2022 Oct 1;154.
54. Ahmad Z. *Praktis COVID-19*. 2nd ed. Palembang; 2021.
55. Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy. *Medicina (Lithuania)*. 2022 Feb 1;58(2).
56. Matthay MA, Thompson BT, Ware LB. The Berlin definition of acute respiratory distress syndrome: Should patients receiving high-flow nasal oxygen be included? *Lancet Respir Med*. 2021 Aug 1;9(8):933–6.

57. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *New England Journal of Medicine*. 2020 Mar 19;382(12):1177–9.
58. Chang Y, Bai M, You Q. Associations between serum interleukins (IL-1 β , IL-2, IL-4, IL-6, IL-8, and IL-10) and disease severity of COVID-19: A systematic review and meta-analysis. *Biomed Res Int*. 2022;2022.
59. Wang X, Li X, Shang Y, Wang J, Zhang X, Su D, et al. Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): A retrospective cohort study in A single medical center. *Epidemiol Infect*. 2020.
60. Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. *American Journal of Emergency Medicine*. 2021 Aug 1;46:16–9.
61. Yang AP, Liu JP, Tao WQ, Li HM. The Diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol*. 2020 Jul 1;84.
62. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. 2020.
63. Ridlawati I. Korelasi Platelet to Lymphocyte Ratio (PLR) dengan C-Reactive Protein (CRP) pada COVID-19. Universitas Gadjah Mada; 2022.
64. Li CH, Chiou HYC, Lin MH, Kuo CH, Lin YC, Lin YC, et al. Immunological map in COVID-19. *Journal of Microbiology, Immunology and Infection*. 2021 Aug 1;54(4):547–56.
65. Serban D, Papanas N, Dascalu AM, Kempler P, Raz I, Rizvi AA, et al. Significance of neutrophil to lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in diabetic foot ulcer and potential new therapeutic targets. *International Journal of Lower Extremity Wounds*. 2021.
66. Lusiantary R. Gambaran rasio neutrofil/limfosit pada kasus preeklamsia. [Padang]: Universitas Andalas; 2021.
67. Warman FA. Hubungan neutrophyl-to-lymphocyte ratio dan platelet-to-lymphocyte ratio dengan tingkat keparahan pasien rawat inap COVID-19 di Rumah Sakit Universitas Andalas. [Padang]: Universitas Andalas; 2023.
68. AHIRWAR AK, TAKHELMAYUM R, SAKARDE A, RATHOD BD, JHA PK, KUMAWAT R, et al. The study of serum hsCRP, ferritin, IL-6 and Plasma D-dimer in COVID-19: A Retrospective Study. *Horm Mol Biol Clin Investig*. 2022 Sep 1;43(3):337–44.
69. Dahlan MS. Besar sampel dalam penelitian kedokteran dan kesehatan. 5th ed. Jakarta: Epidemiologi Indonesia; 2019.
70. Hamza A, Shah N, Azad A, Ghanshyam O, Khan Z. Impact of age, gender and comorbidities affecting the severity of COVID-19 infection in Kashmir. *J Family Med Prim Care*. 2022;11(4):1519.
71. Zimmermann P, Curtis N. Why does the severity of COVID-19 differ with age? understanding the mechanisms underlying the age gradient in

- outcome following SARS-CoV-2 infection. *Pediatric Infectious Disease Journal*. 2022 Feb 1;41(2):E36–45.
72. Chaturvedi R, Lui B, Aaronson JA, White RS, Samuels JD. COVID-19 complications in males and females: recent developments. *J Comp Eff Res*. 2022 Jun 1;11(9):689–98.
 73. Salsabila AS. Karakteristik pasien COVID-19 yang membutuhkan ventilator di Intensive Care Unit (ICU) RSUP M. Djamil Padang tahun 2021. [Padang]: Universitas Andalas; 2022.
 74. Oktavia N, Efrida E, Rofinda ZD. Comparison in levels of interleukin 6, ferritin and neutrophil-lymphocyte ratio in COVID-19 patients treated in ICU and Non-ICU. *Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan*. 2022 Dec 7;16(2).
 75. Tanjung H, Julizar J, Ermayanti S, Herman D, Mahata LE, Putra SP. Profil pasien COVID-19 dengan komorbid yang dirawat di RSUP Dr. M. Djamil Padang. *Jurnal Ilmu Kesehatan Indonesia* [Internet]. 2023 Mar 30;4(1):41–50. <http://jikesi.fk.unand.ac.id/index.php/jikesi/article/view/971>
 76. Jirak P, Mirna M, Van-Almsick V, Shomanova Z, Mahringer M, Lichtenauer M, et al. Gender-specific differences in the intensive care treatment of COVID-19 patients. *J Pers Med*. 2022 May 1;12(5).
 77. Arda LA, Khairisyaf O, Russilawati R, Handayani T. Risk factors associated with 28-day mortality of COVID-19 patients at RSUP Dr. M. Djamil Padang. *Jurnal Respirologi Indonesia*. 2023 Feb 3;43(1):22–33.
 78. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. *Am J Infect Control*. 2021 Feb 1;49(2):238–46.
 79. Findi Z, Indra B, Suharti N, Syahrul MZ, Mulyana R, Yusri E. Hubungan Rasio Neutrofil-Limfosit dengan Derajat Keparahan COVID-19 pada Pasien Diabetes. *Jurnal Ilmu Kesehatan Indonesia* [Internet]. 2023 Jun 15;4(2):124–30. <http://jikesi.fk.unand.ac.id/index.php/jikesi/article/view/1072>
 80. Collado S, Arenas MD, Barbosa F, Cao H, Montero MM, Villar-Garcia J, et al. COVID-19 in grade 4-5 chronic kidney disease patients. *Kidney Blood Press Res*. 2020 Oct 1;45(5):768–74.
 81. Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. *Am J Obstet Gynecol*. 2022 Feb 1;226(2):177–86.
 82. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020 [Internet]. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/downloads/cases-updates/case->
 83. Twanow JDE, McCabe C, Ream MA. The COVID-19 pandemic and pregnancy: impact on mothers and newborns. Vol. 42, *Seminars in Pediatric Neurology*. W.B. Saunders; 2022.
 84. Lopez BJ, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. *New England Journal of Medicine*. 2021 Aug 12;385(7):585–94.

85. Levitus M, Shinker SA, Colvin M. COVID-19 in the critically ill pregnant patient. *Crit Care Clin.* 2022 Jul 1;38(3):521–34.
86. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, et al. Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. *European Journal of Clinical Microbiology & Infectious Diseases* [Internet]. 2020.
87. Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H, et al. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. *Clinica Chimica Acta.* 2020 Oct 1;509:235–43.
88. Muharam M, Ermayanti S, Afriani A. High levels of leucocyte and thrombocyte increasing COVID-19 mortality rate in RSUP Dr. M. Djamil Padang. *Jurnal Respirologi Indonesia.* 2023 Feb 3;43(1):43–9.
89. Simanjuntak A, Kusadhiani I, Latuconsina VZ. Hubungan jumlah trombosit dengan severitas klinis pasien COVID-19 pada tiga rumah sakit rujukan Covid-19 di kota Ambon tahun 2020. *Molucca Medica.* 2022.
90. Barrett TJ, Bilaloglu S, Cornwell M, Burgess HM, Virginio VW, Drenkova K, et al. Platelets contribute to disease severity in COVID-19. *Journal of Thrombosis and Haemostasis.* 2021 Dec 1;19(12):3139–53.
91. Lin J, Yan H, Chen H, He C, Lin C, He H, et al. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. *J Med Virol.* 2021 Feb 1;93(2):934–44.
92. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clinica Chimica Acta.* 2020 Jul 1;506:145–8.
93. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis.* 2020 Sep 1;18(9):2103–9.
94. Hapipah H, Handayati A, Purwaningsih NV. Description of platelet count patients infected with corona virus (COVID-19) with grouping of productive and elderly age. *International Journal of Advanced Health Science and Technology.* 2022 Jan 17;2(1):7–10.
95. Lanini S, Montaldo C, Nicastrì E, Vairo F, Agrati C, Petrosillo N, et al. COVID-19 disease - Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. *PLoS One.* 2020 Dec 1;15(12 December).
96. Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Vol. 18, *Nature Reviews Cardiology.* Nature Research; 2021. p. 666–82.
97. Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. *Pathobiology.* 2021 Jan 1;88(1):15–27.
98. Al-Saadi EAKD, Abdunabi MA. Hematological changes associated with COVID-19 infection. *J Clin Lab Anal.* 2022 Jan 1;36(1).
99. Urbano M, Costa E, Geraldes C. Hematological changes in SARS-COV-2 positive patients. *Hematol Transfus Cell Ther.* 2022 Apr 1;44(2):218–24.
100. Ghizlane EA, Manal M, Abderrahim EK, Abdelilah E, Mohammed M, Rajae A, et al. Lymphopenia in COVID-19: A single center retrospective study of 589 cases. *Annals of Medicine and Surgery.* 2021 Sep 1;69.

101. Toledo SL, Nogueira LS, Carvalho M, Rios DRA, Pinheiro M. COVID-19: Review and hematologic impact. *Clinica Chimica Acta*. 2020 Nov 1;510:170–6.
102. Toori KU, Qureshi MA, Chaudhry A, Safdar MF. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. *Pak J Med Sci*. 2021 Sep 1;37(5):1435–9.
103. Yufani H, Dia Rofinda Z. Limfopenia dan rasio neutrofil-limfosit pada infeksi severe acute respiratory syndrome coronavirus 2 [Internet]. Vol. 10, *Jurnal Kesehatan Andalas*. 2021. <http://jurnal.fk.unand.ac.id>
104. Hidayat R. Nilai netrophil-lymphocyte ratio (NLR) pada pasien COVID-19 dengan dan tanpa komorbid di Rsup Haji Adam Malik Medan. [Medan]: Universitas Sumatera Utara; 2021.
105. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The association between presence of comorbidities and COVID-19 severity: a systematic review and meta-analysis. *Cerebrovascular Diseases*. 2021 Apr 1;50(2):132–40.
106. Carmona-Pérez J, Ioakeim-Skoufa I, Gimeno-Miguel A, Poblador-Plou B, González-Rubio F, Muñozerro-Muñiz D, et al. Multimorbidity profiles and infection severity in COVID-19 population using network analysis in the andalusian health population database. *Int J Environ Res Public Health*. 2022 Apr 1;19(7).
107. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. *National Institutes of Health [Internet]*. 2020.
108. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. *Nat Med*. 2023 Feb 1;29(2):334–43.
109. Alshuweishi Y, Alfaifi M, Almoghrabi Y, Al-Sheikh YA, Alfhili MA. A retrospective analysis of the association of neutrophil–lymphocyte ratio (NLR) with anemia in the Saudi Population. *Medicina (B Aires)*. 2023 Sep 3;59(9):1592.
110. Srivastava A, Bhardwaj A. Prognostic role of NLR and RBS levels in diabetic patients with severe COVID–19 disease. *International journal of scientific research*, (2021).
111. Mhana S, Said H, Zrieki A. NLR and PLR as available and inexpensive markers for evaluation of subclinical inflammation in patients with chronic kidney disease. *Research Journal of Pharmacy and Technology* 2023; 16(1):187-2.
112. Bołtuć K, Bociek A, Dziugiel R, Bociek M, Zapolski T, Dąbrowski W, et al. Neutrophil-Lymphocyte Ratio (NLR) reflects myocardial inhomogeneities in hemodialyzed patients. *Mediators Inflamm*. 2020;2020.
113. Maulana D. Gambaran kadar Neutrophil Lymphocyte Ratio (NLR) pada pasien penyakit jantung koroner di Rumah Sakit Umum Pusat Haji Adam Malik Medan. [Medan, Sumatera Utara]: Universitas Sumatera Utara; 2022.
114. Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. *Arq Bras Cardiol*. 2015 Dec 1;105(6):606–13.

115. Siregar BY, Hasan R, Isnanta R. Association of platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) with global registry of acute coronary events (GRACE) score in acute coronary syndrome. *International Journal of Research and Review*. 2021 May 8;8(5):1–6.
116. Koval DA, Bielosludtseva K. Neutrophil-to-lymphocyte ratio (NLR) as a predictor of survival in COVID-19-associated pneumonia patients (pts).(2022).
117. Zhu F, Ji Y, Huang GX, Zhang Y. Correlations between NLR, NHR, and clinicopathological characteristics, and prognosis of acute ischemic stroke. *Medicine*, (2023).
118. Ergenc H, Ertuek Z, Eminler AT, Cinemre H. Diagnostic and Prognostic Value of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratios on Acute Pancreatitis Patients. *Online Türk Sağlık Bilimleri Dergisi*. 2022 Mar 1;7(1):80–5.
119. Santharaj S, Preethan KN. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and sonological findings in predicting severe cholecystitis. *SAS journal of surgery*, (2022).
120. Lin ZQ, Ma C, Cao WZ, Ning Z, Tan G. Prognostic significance of NLR, PLR, LMR and tumor infiltrating T lymphocytes in patients undergoing surgical resection for hilar cholangiocarcinoma. *Front Oncol*. 2022 Jun 3;12.
121. Garcia-Ortega DY, Ponce-Herrera D, Alvarez-Cano A, Haydee C, Caro-Sánchez S, Luna-Ortiz K. Preoperative neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) as prognostic markers in patients with retroperitoneal liposarcoma. *Surgery in practice and science*, (2022).
122. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer*. 2018 Jul 16;6(1).
123. Jabłońska I, Miszczyk M, Gołowski M, Debosz-Suwinska I, Suwiński R. The prognostic value of RDW, NLR and PLR in sequential radio-chemotherapy for advanced lung cancer. *Nowotwory*, (2022).
124. Firdaus DY, Guyansyah A, Thenu U, Denggo SD. Comparison of neutrophil lymphocyte ratio (NLR), mean platelet volume (MPV) and platelet lymphocyte ratio (PLR) in preeclampsia and normotensive pregnancies. *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*. 2022 Dec 5;54(4).
125. Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil lymphocyte ratio and cardiovascular disease risk: A systematic review and meta-analysis. *Biomed Res Int*. 2018;2018.
126. Peng J, Qi D, Yuan G, Deng X, Mei Y, Feng L, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): A multicenter, cross-sectional study. *J Clin Lab Anal*. 2020 Oct 1;34(10).
127. Ozdemir A, Kocak SY, Karabela SN, Yılmaz M. Can systemic immune inflammation index at admission predict in-hospital mortality in chronic

- kidney disease patients with SARS-CoV-2 infection? *Nefrología*. 2022 Sep;42(5):549–58.
128. Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, et al. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. *Ren Fail*. 2019 Jan 1;41(1):238–43.
 129. Gunawan A, Rosita L, Arthamin MZ, Arifin MS, Apramadha N, Normahayu I, et al. Does End Stage Renal Disease Increase Severity of COVID-19? *Jurnal Penyakit Dalam Udayana Udayana Journal of Internal Medicine [Internet]*. 2023;7(1):12–5. www.jpudnud.org
 130. Aisara S, Azmi S, Yanni M. Gambaran klinis penderita penyakit ginjal kronik yang menjalani hemodialisis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2018;7(1).
 131. Ali J, Olyaei, Edgar V, Lerma. Drug dosing in patients with chronic kidney disease and dermatological diseases. *A* (2015),221-253.
 132. Cohen G. Immune dysfunction in uremia 2020. *Toxins (Basel)*. 2020 Jul 1;12(7).
 133. Moradi EV, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. *American Journal of Emergency Medicine*. 2021 Feb 1;40:11–4.
 134. Marpaung MG, Syoufana RS, Aulia R, Dewantuningrum J. Neutrophil-lymphocyte ratio(NLR) , platelet-lymphocyte ratio (PLR) and D-Dimer to length of stay in ICU of pregnancy with COVID-19 complicating severe coagulopathy. *Indonesian Journal of Obstetrics & Gynecology Science*. 2022.
 135. Syifa SD, Reza M, Rofinda ZD, Antonius PA, Firdawati F, Putri BO. Profil kasus pada ibu hamil yang dirawat dengan COVID-19 di RSUP Dr. M. Djamil Padang periode Januari—Desember 2020. *Jurnal Ilmu Kesehatan Indonesia*. 2023 Jan 19;3(3):249–57.
 136. Klement AH, Hadi E, Asali A, Shavit T, Wisner A, Haikin E, et al. Neutrophils to lymphocytes ratio and platelets to lymphocytes ratio in pregnancy: A population study. *PLoS One*. 2018 May 1;13(5).
 137. Zou K, Chen H, Liu Y. Patients with COVID-19 undergoing cesarean deliveries: Adapting the OR suite and perioperative care to prevent transmission. *AORN J*. 2020 Sep 1;112(3):217–24.
 138. Simadibrata DM, Pandhita BAW, Ananta ME, Tango T. Platelet-to-lymphocyte ratio, a novel biomarker to predict the severity of COVID-19 patients: A systematic review and meta-analysis. *J Intensive Care Soc*. 2022 Feb 1;23(1):20–6.
 139. Bell TD. COVID-19 in the critically ill patient. *Infect Dis Clin North Am*. 2022 Jun 1;36(2):365–77.
 140. D'ascanio M, Innammorato M, Pasquariello L, Pizzirusso D, Guerrieri G, Castelli S, et al. Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes. *BMC Geriatr*. 2021 Dec 1;21(1).

141. Wang X, Zheng X, Yan J, Xu R, Xu M, Zheng L, et al. The clinical values of afamin, triglyceride and PLR in predicting risk of gestational diabetes during early pregnancy. *Front Endocrinol (Lausanne)*. 2021 Nov 3;12.

